Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.

What Was Tested

The paper reports a study of Leuprolide, published as a controlled clinical trial.

To distinguish which children with precocious puberty (PP) and early puberty (EP) should be treated and which followed without therapy.

Who Took Part

The abstract describes 21 girls taking part.

PubMed indexes the participants as children, women only.

Sixteen females with PP or EP with a mean chronological age (CA) of 8.8 +/- 1.4 years and a mean bone age (BA) of 10.8 +/- 1.3 years were treated for a mean of 2.7 +/- 1.0 years with a GnRH analog (triptorelin or leuprolide acetate; group A), while 21 girls with a mean CA of 8.5 +/- 1.0 years, a mean BA of 9.7 +/- 1.4 years and a predicted adult height of >155 cm were followed without therapy (group B).

Criteria for treatment were one of: a. predicted adult height (PAH) of <155 cm initially or at any time during follow up; b.

What Was Measured

PubMed files the paper under topics including Body Height, Bone Development, Gonadotropin-Releasing Hormone, Gonadotropins, Growth Disorders, Leuprolide and Puberty.

What This Means in Plain Language

This is a controlled clinical trial of Leuprolide in 21 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the related Leuprolide library page, all human trials.